EP1246843A1 - Nouvel homologue du fgf, zfgf12 - Google Patents
Nouvel homologue du fgf, zfgf12Info
- Publication number
- EP1246843A1 EP1246843A1 EP01901722A EP01901722A EP1246843A1 EP 1246843 A1 EP1246843 A1 EP 1246843A1 EP 01901722 A EP01901722 A EP 01901722A EP 01901722 A EP01901722 A EP 01901722A EP 1246843 A1 EP1246843 A1 EP 1246843A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- residue
- zfgf12
- polypeptide
- cells
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Definitions
- a “protein” is a macromolecule comprising one or more polypeptide chains.
- a protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.
- the term "receptor” denotes a cell-associated protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell.
- Membrane-bound receptors are characterized by a multi-peptide structure comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids.
- the above conditions are meant to serve as a guide and it is well within the abilities of one skilled in the art to adapt these conditions for use with a particular polypeptide hybrid.
- the T m for a specific target sequence is the temperature (under defined conditions) at which 50% of the target sequence will hybridize to a perfectly matched probe sequence.
- Those conditions which influence the T ⁇ include, the size and base pair content of the polynucleotide probe, the ionic strength of the hybridization solution, and the presence of destabilizing agents in the hybridization solution.
- Insect cells can be infected with recombinant baculovirus, commonly derived from Autographa californica nuclear polyhedrosis virus (AcNPV).
- AcNPV Autographa californica nuclear polyhedrosis virus
- a preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate.
- Other drug resistance genes e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase
- hygromycin resistance e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase
- Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA), Octyl-Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like.
- Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross- linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used.
- Protein synthesis may be evaluated, for example, by comparing precipitation of 35 S-methionine-labeled proteins following incubation of the test cells with s S-methionine and 35 S-methionine and a putative modulator of protein synthesis.
- Thermogenesis may be evaluated as described by B. Stanley in The Biology of Neuropeptide Y and Related Peptides, W. Colmers and C. Wahlestedt (eds.),
- assays known to those skilled in the art can be utilized to detect antibodies which specifically bind to zFGF12 proteins or peptides. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, radioimmuno- precipitation, enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for binding to wild-type versus mutant zFGF12 protein or peptide.
- Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances.
- a known target can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances.
- ischemia and reperfusion are important contributors to tissue necrosis, such as a myocardial infarct or stroke.
- the molecules of the present invention will have therapeutic value to reduce damage to the tissues caused by ischemia or ischemia-reperfusion events, particularly in the heart or brain.
- Other therapeutic uses for the present invention include induction of skeletal muscle neogenesis and/or hype ⁇ lasia, kidney regeneration and/or for treatment of systemic and pulmonary hypertension.
- the white, virus/PEG precipitate from 2 bottles is resuspended in 2.5 ml PBS.
- the resulting virus solution is placed in 2-ml microcentrifuge tubes and centrifuged at 14,000 X G in the microcentrifuge for 10 minutes to remove any additional cell debris.
- the supernatant from the 2-ml microcentrifuge tubes is transferred into a 15-ml polypropylene snapcap tube and adjusted to a density of 1.34 g/ml with CsCl.
- the solution is transferred to 3.2-ml, polycarbonate, thick-walled centrifuge tubes and spun at 348,000 X G for 3-4 hours at 25?C.
- the virus forms a white band. Using wide-bore pipette tips, the virus band is collected.
Abstract
La présente invention concerne des molécules polynucléotidiques et polypeptidiques du zFGF12, un nouveau membre de la famille des FGF. La présente invention concerne également des anticorps des polypeptides du zFGF12, et des méthodes d'utilisation des polynucléotides et des polypeptides.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47806200A | 2000-01-05 | 2000-01-05 | |
US478062 | 2000-01-05 | ||
PCT/US2001/000238 WO2001049740A1 (fr) | 2000-01-05 | 2001-01-04 | Nouvel homologue du fgf, zfgf12 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1246843A1 true EP1246843A1 (fr) | 2002-10-09 |
Family
ID=23898370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01901722A Withdrawn EP1246843A1 (fr) | 2000-01-05 | 2001-01-04 | Nouvel homologue du fgf, zfgf12 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1246843A1 (fr) |
JP (1) | JP2003518944A (fr) |
AU (1) | AU2759201A (fr) |
CA (1) | CA2396401A1 (fr) |
WO (1) | WO2001049740A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2398603A1 (fr) * | 2000-02-15 | 2001-08-23 | Amgen, Inc. | Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants |
EP1947182A1 (fr) * | 2000-02-15 | 2008-07-23 | Amgen Inc. | Molécules 23 à facteur de croissance de fibroblaste et utilisations associées |
AU2001249125A1 (en) * | 2000-03-08 | 2001-09-17 | Chiron Corporation | Human fgf-23 gene and gene expression products |
US20030105302A1 (en) * | 2000-03-08 | 2003-06-05 | Nobuyuki Itoh | Human FGF-23 gene and gene expression products |
KR20090036151A (ko) | 2000-07-19 | 2009-04-13 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 | 신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법 |
CN100387713C (zh) | 2000-08-11 | 2008-05-14 | 麒麟医药株式会社 | 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna |
ATE441666T1 (de) * | 2001-12-28 | 2009-09-15 | Kyowa Hakko Kirin Co Ltd | Antikírper gegen den fibroblastenwachstumsfaktor 23 |
EP1728514A1 (fr) * | 2005-06-03 | 2006-12-06 | Immunotech S.A. | Utilisations d'oligonucléotides stimulateurs de cellules souches mésenchymateuses |
US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
SG10201806648TA (en) | 2011-07-01 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Compositions, uses and methods for treatment of metabolic disorders and diseases |
US9963494B2 (en) | 2012-11-28 | 2018-05-08 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
CN105008548B (zh) | 2012-12-27 | 2020-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法 |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
MX2016004822A (es) | 2013-10-28 | 2016-08-17 | Ngm Biopharmaceuticals Inc | Modelos de cancer y metodos asociados. |
LT3097122T (lt) | 2014-01-24 | 2020-07-27 | Ngm Biopharmaceuticals, Inc. | Antikūnai, surišantys beta kloto domeną 2, ir jų panaudojimo būdai |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
CA2951153A1 (fr) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Procedes et utilisations pour la modulation de l'homeostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire |
IL251834B2 (en) | 2014-10-23 | 2023-09-01 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions containing peptide variants and methods of using them |
WO2016073855A1 (fr) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
CA3003616C (fr) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methodes de traitement de troubles associes aux acides biliaires |
AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859208A (en) * | 1988-07-06 | 1999-01-12 | Fiddes; John C. | Human basic fibroblast growth factor analog |
WO1989000198A1 (fr) * | 1987-07-07 | 1989-01-12 | Biotechnology Research Associates, J.V. | Facteurs de croissance de fibroblastes recombinants |
CA2218329A1 (fr) * | 1995-06-05 | 1996-12-12 | Human Genome Sciences, Inc. | Facteur ii de croissance des fibroblastes |
AU733222B2 (en) * | 1997-11-25 | 2001-05-10 | Genentech Inc. | Fibroblast growth factor-19 |
-
2001
- 2001-01-04 CA CA002396401A patent/CA2396401A1/fr not_active Abandoned
- 2001-01-04 EP EP01901722A patent/EP1246843A1/fr not_active Withdrawn
- 2001-01-04 AU AU27592/01A patent/AU2759201A/en not_active Abandoned
- 2001-01-04 JP JP2001550280A patent/JP2003518944A/ja active Pending
- 2001-01-04 WO PCT/US2001/000238 patent/WO2001049740A1/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO0149740A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2003518944A (ja) | 2003-06-17 |
WO2001049740A1 (fr) | 2001-07-12 |
CA2396401A1 (fr) | 2001-07-12 |
AU2759201A (en) | 2001-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080124759A1 (en) | Novel fgf homolog zfgf12 | |
US20020081663A1 (en) | Novel FGF homolog ZFGF11 | |
WO2001049849A1 (fr) | Zfgf11 : nouvel homologue de fgf | |
WO2001049740A1 (fr) | Nouvel homologue du fgf, zfgf12 | |
KR100611063B1 (ko) | 섬유아세포 성장인자 상동체 | |
US7563438B2 (en) | FGF homologs and antibodies thereto | |
US20050240014A1 (en) | Connective tissue growth factor homologs | |
WO1999055869A1 (fr) | Nouveaux facteurs et materiels de croissance polypeptidiques et leurs procedes de production | |
WO1999032515A2 (fr) | Homologue de l'angiopoietine, adn le codant et procede de production dudit homologue | |
US7135317B2 (en) | Polynucleotides encoding disintegrin homologs, and related products | |
US20020031805A1 (en) | Novel FGF homolog zFGF10 | |
AU1622200A (en) | Mammalian chondromodulin-like protein | |
US6531576B1 (en) | Four-helical bundle protein zsig81 | |
WO1999040193A1 (fr) | Zapo3 homologue d'angiopoietine, adn le codant et sa methode de production | |
WO2001047957A2 (fr) | NOUVEL HOMOLOGUE zFGF10 DE LA FAMILLE FGF | |
EP1204681A2 (fr) | Cytokine zalpha48 a enroulement en helice | |
EP1054967A1 (fr) | Homologues du facteur de croissance pour le tissu conjonctif | |
EP1181369B1 (fr) | Proteine en faisceau a quatre helices zsig81 | |
WO2001070986A2 (fr) | Proteine helicoidale zalpha51 | |
WO2001018205A1 (fr) | Polypeptide secrete zalpha30 | |
MXPA00008094A (en) | Connective tissue growth factor homologs | |
CA2377580A1 (fr) | Polypeptide spirale zalpha29 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020711 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
D17D | Deferred search report published (deleted) | ||
17Q | First examination report despatched |
Effective date: 20050111 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090801 |